Results 181 to 190 of about 15,126 (225)
Some of the next articles are maybe not open access.

Psilocybin

Reactions Weekly, 2023
Abstract Psilocybin is a psychoactive drug found in a variety of mushroom species around the world. It induces an altered state of consciousness that has been used in ceremonial settings since antiquity. It is now known beyond doubt that the psychoactive effect of psilocybin (more particularly, its active metabolite psilocin) is due to a
James J. Rucker, David Erritzoe
openaire   +2 more sources

Psilocybin-induced takotsubo cardiomyopathy

BMJ Case Reports, 2022
We present a case of takotsubo cardiomyopathy following recreational ingestion of Psilocybe semilanceata (known as ‘magic mushrooms’). The patient presented with respiratory distress and pulmonary oedema responding to standard medical measures. Investigations included: echocardiogram, cardiac MRI and angiogram.
Wiktoria Julia Kotts   +3 more
openaire   +2 more sources

Psilocybin administration

Journal of Prescribing Practice, 2022
George Winter looks at the possibilities of incorporating psilocybin administration into healthcare
openaire   +1 more source

Psilocybin's Erasure of EGO

The Psychoanalytic Review, 2023
The psychoanalytic journey and the psilocybin journey both reveal unconscious dynamics. In this article a psychoanalyst discusses his own psilocybin journey. Similarities and differences between these journeys are discussed. Possibilities are offered for a dialogue in which psilocybin may contribute to psychoanalytic understanding and psychoanalysis ...
openaire   +2 more sources

ALSUntangled #77: Psilocybin

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
ALSUntangled reviews alternate and off-label treatments prompted by patient interest. Here, we review psilocybin, a chemical derived from mushrooms and belonging in the category of drugs known as psychedelics. Psilocybin has plausible mechanisms for slowing ALS progression because of its ability to cross the blood brain barrier and effect neurogenesis ...
Bhavya Bakshi   +27 more
openaire   +2 more sources

The pharmacology of psilocybin

Addiction Biology, 2002
AbstractPsilocybin (4‐phosphoryloxy‐N,N‐dimethyltryptamine) is the major psychoactive alkaloid of some species of mushrooms distributed worldwide.These mushrooms represent a growing problem regarding hallucinogenic drug abuse. Despite its experimental medical use in the 1960s, only very few pharmacological data about psilocybin were known until ...
Torsten, Passie   +3 more
openaire   +2 more sources

Psilocybin for Trauma-Related Disorders

2022
Posttraumatic stress disorder (PTSD) is a debilitating, chronic disorder and efficacy rates of current PTSD treatments are underwhelming. There is a critical need for innovative approaches. We provide an overview of trauma and PTSD and cite literature providing converging evidence of the therapeutic potential of psilocybin for PTSD.
Amanda J, Khan   +3 more
openaire   +2 more sources

Availability of Websites Offering to Sell Psilocybin Spores and Psilocybin

Journal of Psychoactive Drugs, 2009
This study assesses the availability of websites offering to sell psilocybin spores and psilocybin, a powerful hallucinogen contained in Psilocybe mushrooms. Over a 25-month period beginning in March 2003, eight searches were conducted in Google using the term "psilocybin spores." In each search the first 100 nonsponsored links obtained were scored by ...
Jason P, Lott   +2 more
openaire   +2 more sources

Sixty seconds on . . . psilocybin

BMJ, 2016
Not so fast. There’s a long way to go. But a study in London has shown that the active ingredient in magic mushrooms, psilocybin, may be effective against treatment resistant depression. Its effects were quick—within a week—and more than 40% of the patients treated were still in remission three months later.1 Yes, as far as it goes.
openaire   +2 more sources

Home - About - Disclaimer - Privacy